دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A preprocedural risk score predicts acute kidney injury following primary percutaneous coronary intervention
Stefano Buratti MD,Gabriele Crimi MD,Alberto Somaschini MD,Stefano Cornara MD,Rita Camporotondo MD,Nicola Cosentino MD,Marco Moltrasio MD,Mara Rubino MD,Monica De Metrio MD,Ivana Marana MD,Stefano De Servi MD,Giancarlo Marenzi MD,Gaetano M. De Ferrari MD
doi : 10.1002/ccd.29176
Volume 98, Issue 2 p. 197-205
Reliable preprocedural risk scores for the prediction of Contrast-Induced Acute Kidney Injury (CI-AKI) following Percutaneous Coronary Intervention (pPCI) in patients with ST-elevation myocardial infarction (STEMI) are lacking. Aim of this study was to derive and validate a preprocedural Risk Score in this setting.
Assessing the risk of acute kidney injury after primary PCI: The simpler the sooner the better
Davide Cao MD,George D. Dangas MD, PhD
doi : 10.1002/ccd.29851
Volume 98, Issue 2 p. 206-207
Successful modeling of long term outcomes in end-stage renal disease patients undergoing percutaneous coronary intervention with drug-eluting stents
Aaron N. Dunn BA,Chetan Huded MD,Russell Raymond DO,A. Michael Lincoff MD,Christopher Bajzer MD,Samir Kapadia MD,Stephen G. Ellis MD
doi : 10.1002/ccd.29707
Volume 98, Issue 2 p. 208-214
The objective of this study is to identify and model risk factors for major adverse cardiac events (MACE) and all-cause mortality among patients with ESRD treated with PCI using DES.
Percutaneous coronary intervention in end-stage kidney disease: Trapped between a rock and a hard place
Gautam R. Shroff MBBS, FACC,Timothy D. Henry MD
doi : 10.1002/ccd.29846
Volume 98, Issue 2 p. 215-216
Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the United States
Santiago Garcia MD,Larissa Stanberry PhD,Christian Schmidt MS,Scott Sharkey MD,Michael Megaly MD,Mazen S. Albaghdadi MD,Perwaiz M. Meraj MD,Ross Garberich MS, MBA,Farouc A. Jaffer MD, PhD,Ada C. Stefanescu Schmidt MD MSc,Simon R. Dixon MBChB,Jeffrey J. Rade MD,Timothy Smith MD,Mark Tannenbaum MD,Jenny Chambers MBA,Frank Aguirre MD,Paul P. Huang MD, MSc,Dharam J. Kumbhani MD, SM, MRCP,Thomas Koshy MD,Dmitriy N. Feldman MD,Jay Giri MD, MPH,Prashant Kaul MD,Craig Thompson MD,Houman Khalili MD,Brij Maini MD,Keshav R. Nayak MD,Mauricio G. Cohen MD,Sripal Bangalore MD, MHA,Binita Shah MD, MS,Timothy D. Henry MD
doi : 10.1002/ccd.29154
Volume 98, Issue 2 p. 217-222
To evaluate the impact of COVID-19 pandemic migitation measures on of ST-elevation myocardial infarction (STEMI) care.
Practice patterns for patients with ST-elevation myocardial infarction during the early phase of the COVID-19 pandemic—Valuable lessons learned
Xiaoming Jia MD,Hani Jneid MD
doi : 10.1002/ccd.29843
Volume 98, Issue 2 p. 223-224
Intravascular lithotripsy in calcified-coronary lesions: A real-world observational, European multicenter study
Amir Aziz MRCP, PhD,Gurbir Bhatia MD, MRCP,Michael Pitt MD, MRCP,Anirban Choudhury MD, MRCP,Ahmed Hailan MD, FRCP,Subramanya Upadhyaya MD, MRCP,Leong Lee MD, MRCP,Luca Testa MD,Matteo Casenghi MD,Alfonso Ielasi MD,Bernardo Cortese MD,Hannah Rides MSc,Sandeep Basavarajaiah MD, MRCP, FESC
doi : 10.1002/ccd.29263
Volume 98, Issue 2 p. 225-235
The recently introduced intravascular lithotripsy (IVL) appears promising and relatively safer than conventional approaches when dealing with calcified lesions. Although there are published reports on this novel technology, data from the real world are limited. In this study, we aim to report on the experience of IVL from a real-world population derived from six European centers that undertake high-volume complex coronary interventions.
Intravascular lithotripsy for calcified coronary arteries in the real-world: From rock to metal
Ashok Seth FRCP, MSCAI, FACC, FESC, DSc,Vijay Kumar MD, DNB (Cardiology)
doi : 10.1002/ccd.29853
Volume 98, Issue 2 p. 236-237
Management and outcomes of coronary artery perforations treated with the block and deliver technique
Jorge Sanz Sanchez MD, PhD,Roberto Garbo MD,Andrea Gagnor MD,Jacopo Oreglia MD,Pietro Mazzarotto MD,Matteo Maurina MD,Damiano Regazzoli MD,Gabriele L. Gasparini MD
doi : 10.1002/ccd.29241
Volume 98, Issue 2 p. 238-245
Coronary artery perforation (CAP) is a potentially life-threatening complication during percutaneous coronary interventions (PCI) and the best strategy for its management is yet to be proved. We aimed to analyze the safety, efficacy, and long-term clinical outcomes of the block and deliver (BAD) technique, as only anecdotal cases are reported in literature.
End-stage renal disease as an independent risk factor for in-hospital mortality after coronary drug-eluting stenting: Understanding and modeling the risk
Aaron N. Dunn BA,Chetan Huded MD, MSc,Conrad Simpfendorfer MD,Russell Raymond DO,Samir Kapadia MD,E. Murat Tuzcu MD,Stephen G. Ellis MD
doi : 10.1002/ccd.28929
Volume 98, Issue 2 p. 246-254
We sought to compare in-hospital outcomes between patients with and without end-stage renal disease (ESRD) undergoing coronary drug-eluting stent (DES) placement and to model risk of in-hospital adverse postpercutaneous coronary intervention (PCI) events in ESRD patients.
SCAI expert consensus update on best practices in the cardiac catheterization laboratory
Srihari S. Naidu MD, FACC, FAHA, FSCAI (Chair),J. Dawn Abbott MD, FACC, FSCAI,Jayant Bagai MD, FSCAI,James Blankenship MD, MSc, MSCAI,Santiago Garcia MD, FACC, FSCAI,Sohah N. Iqbal MD, FACC, FSCAI,Prashant Kaul MD, FSCAI,Matheen A. Khuddus MD, FACC, FSCAI,Lorrena Kirkwood RN, BSN, MS,Steven V. Manoukian MD, FACC, FAHA, FSCAI,Manesh R. Patel MD, FAHA,Kimberly Skelding MD, FACC, FAHA, FSCAI,David Slotwiner MD, FACC, FHRS,Rajesh V. Swaminathan MD, FSCAI,Frederick G. Welt MD, FACC, FSCAI,Daniel M. Kolansky MD, FACC, FAHA, FSCAI (Vice-Chair)
doi : 10.1002/ccd.29744
Volume 98, Issue 2 p. 255-276
The current document commissioned by the Society for Cardiovascular Angiography and Interventions (SCAI) and endorsed by the American College of Cardiology, the American Heart Association, and Heart Rhythm Society represents a comprehensive update to the 2012 and 2016 consensus documents on patient-centered best practices in the cardiac catheterization laboratory. Comprising updates to staffing and credentialing, as well as evidence-based updates to the pre-, intra-, and post-procedural logistics, clinical standards and patient flow, the document also includes an expanded section on CCL governance, administration, and approach to quality metrics. This update also acknowledges the collaboration with various specialties, including discussion of the heart team approach to management, and working with electrophysiology colleagues in particular. It is hoped that this document will be utilized by hospitals, health systems, as well as regulatory bodies involved in assuring and maintaining quality, safety, efficiency, and cost-effectiveness of patient throughput in this high volume area.
Racial and ethnic disparities in coronary, vascular, structural, and congenital heart disease
Cindy L. Grines MD, MSCAI,Andrew J. Klein MD, FSCAI,Holly Bauser-Heaton MD, PhD, FSCAI,Mohamad Alkhouli MD, FSCAI,Neelima Katukuri MD, FSCAI,Varun Aggarwal MD, FSCAI,S. Elissa Altin MD, FSCAI,Wayne B. Batchelor MD, FSCAI,James C. Blankenship MD, MSCAI,Foluso Fakorede MD,Beau Hawkins MD, FSCAI,Gabriel A. Hernandez MD,Nkechinyere Ijioma MBBS,Britton Keeshan MD, MPH,Jun Li MD, FSCAI,R. Allen Ligon MD,Andres Pineda MD, FSCAI,Yader Sandoval MD, FSCAI,Michael N. Young MD
doi : 10.1002/ccd.29745
Volume 98, Issue 2 p. 277-294
Cardiovascular disease (CVD) remains the leading cause of death in the United States. However, percutaneous interventional cardiovascular therapies are often underutilized in Blacks, Hispanics, and women and may contribute to excess morbidity and mortality in these vulnerable populations. The Society for Cardiovascular Angiography and Interventions (SCAI) is committed to reducing racial, ethnic, and sex-based treatment disparities in interventional cardiology patients. Accordingly, each of the SCAI Clinical Interest Councils (coronary, peripheral, structural, and congenital heart disease [CHD]) participated in the development of this whitepaper addressing disparities in diagnosis, treatment, and outcomes in underserved populations. The councils were charged with summarizing the available data on prevalence, treatment, and outcomes and elucidating potential reasons for any disparities. Given the huge changes in racial and ethnic composition by age in the United States (Figure 1), it was difficult to determine disparities in rates of diagnosis and we expected to find some racial differences in prevalence of disease. For example, since the average age of patients undergoing transcatheter aortic valve replacement (TAVR) is 80?years, one may expect 80% of TAVR patients to be non-Hispanic White. Conversely, only 50% of congenital heart interventions would be expected to be performed in non-Hispanic Whites. Finally, we identified opportunities for SCAI to advance clinical care and equity for our patients, regardless of sex, ethnicity, or race.
Re-instituting a live cardiology meeting without symptomatic COVID-19 transmission
David G. Rizik MD, FACC, MSCAI,Sunil V. Rao MD, FACC,Gregg W. Stone MD, FACC, MSCAI,Robert F. Burke MD, FASE, FSCAI,James B. Hermiller MD, FACC, MSCAI,William W. O'Neill MD, FACC, MSCAI
doi : 10.1002/ccd.29748
Volume 98, Issue 2 p. 295-296
End-stage renal disease patients undergoing angioplasty and bypass for critical limb ischemia have worse outcomes compared to non-ESRD patients: Systematic review and meta-analysis
Desireé B. Dawson MD,Nelson A. Telles-Garcia MD,Jessica L. Atkins MD,George S. Mina MD,Adrian P. Abreo MD,Chiranjiv S. Virk MD,Paari S. Dominic MD
doi : 10.1002/ccd.29688
Volume 98, Issue 2 p. 297-307
End-stage renal disease (ESRD) is associated with increased morbidity and mortality following lower extremity amputation for critical limb ischemia (CLI). Angioplasty and bypass are used in ESRD patients with CLI; however, the treatment of choice remains controversial. We compared the long-term outcomes in patients with CLI undergoing angioplasty or bypass to evaluate the differences between patients with ESRD and those without ESRD.
Critical limb ischemia in the end stage renal disease patient: Some next steps
John G. Winscott MD,William B. Hillegass MD, PhD
doi : 10.1002/ccd.29852
Volume 98, Issue 2 p. 308-309
Clinical outcomes of patients with and without chronic kidney disease undergoing endovascular revascularization of infrainguinal peripheral artery disease: Insights from the XLPAD registry
Ryan Kabir MD,Suchith Vuppala MD,Yulun Liu PhD,Ishita Tejani BDS, MS, MSPH,Rick Weideman PharmD,Avantika Banerjee MS,Shirling Tsai MD,Lynn Huffman MD,Khusrow Niazi MD,Emmanouil S. Brilakis MD, PhD,Mehdi H. Shishehbor DO, MPH, PhD,Subhash Banerjee MD
doi : 10.1002/ccd.29491
Volume 98, Issue 2 p. 310-316
The purpose of the present study was to define clinical outcomes of chronic kidney disease (CKD) patients undergoing endovascular revascularization of infrainguinal peripheral artery disease (PAD).
It is all about the beans: How chronic kidney disease can affect outcomes in peripheral intervention
Nachiket J. Patel MD,Richard R. Heuser MD
doi : 10.1002/ccd.29850
Volume 98, Issue 2 p. 317-318
Long-term outcomes after transcatheter aortic valve replacement with minimal contrast in chronic kidney disease
Justyna Rzucidlo MD,Vita Jaspan MD,Darien Paone MD,Hasan Jilaihawi MD,Yuhe Xia MS,Anna Kapitman BA,Makoto Nakashima MD, PhD,Yuxin He MD,Homam Ibrahim MD,Illya Pushkar MPH,Peter J. Neuburger MD,Muhamed Saric MD,Daniel Bamira MD,Sonja Paschke MD,Chloe Kalish BA,Cezar Staniloae MD,Binita Shah MD,Mathew Williams MD
doi : 10.1002/ccd.29378
Volume 98, Issue 2 p. 319-327
Patients with renal insufficiency have poor short-term outcomes after transcatheter aortic valve replacement (TAVR).
Transcatheter aortic valve replacement and chronic kidney disease: Close friends or sworn enemies?
Giuseppe Tarantini MD, PhD,Francesco Cardaioli MD
doi : 10.1002/ccd.29854
Volume 98, Issue 2 p. 328-329
Incidence and outcomes of acute kidney injury stratified by cardiogenic shock severity
Mitchell Padkins MD,Thomas Breen MD,Sean Van Diepen MD, MSc,Gregory Barsness MD,Kianoush Kashani MD, MS,Jacob C. Jentzer MD
doi : 10.1002/ccd.29692
Volume 98, Issue 2 p. 330-340
Acute kidney injury (AKI) is common among patients with cardiogenic shock (CS) and it is independently associated with mortality. We sought to assess the prevalence, severity, and prognosis of AKI as a function of cardiogenic shock severity in unselected Cardiac Intensive Care Unit (CICU) patients.
Acute kidney injury in cardiogenic shock: The powerful distortions of survivor bias
David M. Tehrani MD, MS,Arnold H. Seto MD, MPA
doi : 10.1002/ccd.29848
Volume 98, Issue 2 p. 341-342
In-hospital outcomes of transcatheter mitral valve repair in patients with and without end stage renal disease: A national propensity match study
Muhammad Zia Khan MD,Salman Zahid MD,Muhammad U. Khan MD,Asim Kichloo MD,Shakeel Jamal MD,Abdul Mannan Khan Minhas MD,Muhammad Bilal Munir MD,Sudarshan Balla MD
doi : 10.1002/ccd.29517
Volume 98, Issue 2 p. 343-351
To study trends of utilization, outcomes, and cost of care in patients undergoing undergoing transcatheter mitral valve repair (TMVr) with end-stage renal disease (ESRD).
Transcatheter aortic valve thrombosis: Data from a French multicenter cohort analysis
Thomas Mouyen MD,Thibaut Manigold MD,Jean-Philippe Collet MD, PhD,Eric Durand MD, PhD,Christophe Barbey MD,Thibault Lhermusier MD,Didier Tchetche MD,Thomas Chollet MD,Aurélien Mulliez Msc,Pascal Motreff MD, PhD,Nicolas Combaret MD,Géraud Souteyrand MD
doi : 10.1002/ccd.29555
Volume 98, Issue 2 p. 352-362
To evaluate the effectiveness of anticoagulant therapies in patients with clinical transcatheter heart valve (THV) thrombosis, to describe complications, and to assess their risk profile was the objectives.
Transcatheter aortic valve thrombosis: The more we see the more we know
Anna Franzone MD, PhD,Giovanni Esposito MD, PhD
doi : 10.1002/ccd.29845
Volume 98, Issue 2 p. 363-364
Transcatheter aortic valve implantation for degenerated aortic valves: Experience with a new supra-annular device. The Spanish Allegra valve-in-valve (SAVIV) registry
Ra?l Moreno MD, PhD,José-Antonio Baz MD,José Moreu MD, PhD,Alberto Berenguer MD,Ariana Gonz?lvez-Garc?a MD,Guillermo Galeote MD, PhD,Ubaldo Hern?ndez MD,Tom?s Cant?n MD,Santiago Jiménez-Valero MD,Alfonso Jurado-Rom?n MD, PhD,Halley Moya MD,Esther L?zaro MD
doi : 10.1002/ccd.29742
Volume 98, Issue 2 p. 365-370
The objective was to evaluate the results of valve-in-valve procedures performed with the Allegra device.
Clinical evaluation of the Hydra self-expanding transcatheter aortic valve: 6 month results from the GENESIS trial
Praveen Chandra MD, DM, FACC, FESC, FSCAI, FAPSIC,John Jose MD, DM,Shafeeq Mattummal MD, DM, FESC, FSCAI, FACC,Ajaykumar U. Mahajan MD, DM, FICP, FACC, FESC, FSCAI,Sajeev C. Govindan MD, DM, PhD, FACC, FESC,Chandrashekhar N. Makhale MD, DNB, FCSI, FACC, FSCAI, FESC,Sharad Chandra MD, DM, FACC, FESC, FSCAI,Ranjan Shetty MD, DM, FACC, FESC, FSCAI, MBA,Sandeep Mohanan MD, DM, DNB,John F. John MD, DM,Sanjay Mehrotra MD, DM,Lars S?ndergaard MD, DMSc
doi : 10.1002/ccd.29733
Volume 98, Issue 2 p. 371-379
To evaluate the safety and performance of the Hydra transcatheter aortic valve (THV) in the treatment of symptomatic severe aortic stenosis in patients at high or extreme surgical risk.
New TAVR item added to cart for large scale clinical testing
Jorge A. Belardi MD, FSCAI, FACC,Pablo M. Lamelas MD, MSc
doi : 10.1002/ccd.29855
Volume 98, Issue 2 p. 380-381
Management of peri-device leak following left atrial appendage closure: A systematic review
Jose R. Sleiman MD,Antonio J. Lewis MD,Eduardo J. Perez MD,Alexandra M. Sanchez MD,Jose L. Baez-Escudero MD,Jose L. Navia MD,Craig R. Asher MD,Robert J. Cubeddu MD
doi : 10.1002/ccd.29495
Volume 98, Issue 2 p. 382-390
This study aimed to examine the cumulative experience of peri-device leak (PDL) closure following left atrial appendage (LAA) closure.
The role of peri-device leak closure after left atrial appendage occlusion: A safe and feasible approach
Giuseppe Musumeci MD,Stefania Civera MD
doi : 10.1002/ccd.29856
Volume 98, Issue 2 p. 391-392
Predicting complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy using a risk stratification model and clinical tool
Ahmadreza Karimianpour DO,Justin Heizer MD,Davis Leaphart BS,Jeremy D. Rier DO,Shawn Shaji MD,Viswanathan Ramakrishnan PhD,Christopher D. Nielsen MD,Valerian L. Fernandes MD,Michael R. Gold MD, PhD
doi : 10.1002/ccd.29478
Volume 98, Issue 2 p. 393-400
Alcohol septal ablation (ASA) is a proven method of septal reduction for patients with drug refractory, symptomatic hypertrophic obstructive cardiomyopathy (HOCM). This procedure is associated with a 6.5–11% risk of complete heart block (CHB).
Individualizing risk assessment for conduction system injury after alcohol septal ablation
Alexander Postalian MD,Zvonimir Krajcer MD
doi : 10.1002/ccd.29849
Volume 98, Issue 2 p. 401-402
CoreValve bioprosthesis dysfunction treated with a Sapien 3 valve-in-valve transcatheter aortic valve replacement and BASILICA technique
Ravi K Sharma MD,Mark K Tuttle MD,Marie-France Poulin MD,Roger J Laham MD
doi : 10.1002/ccd.29544
Volume 98, Issue 2 p. 403-406
Structural deterioration of transcatheter heart valve (THV) has been previously described. With the expansion of transcatheter aortic valve replacement (TAVR) indications toward treating lower risk patients with longer life expectancy, there will be increased necessity of managing the patients with THV dysfunction including those at risk for coronary obstruction or sinus sequestration. Coronary access also remains a challenge in such cases with THV dysfunction undergoing valve-in-transcatheter heart valve (ViTHV) TAVR. A unique and first reported case of THV deterioration treated with Sapien 3 ViTHV-TAVR inside a 31?mm CoreValve bioprosthesis along with left coronary leaflet laceration using the BASILICA technique has been presented.
Unmasking psychological reasons of delay in acute coronary syndromes presentation during the COVID-19 pandemic
Antonio Greco MD,Marco Spagnolo MD,Davide Capodanno MD, PhD
doi : 10.1002/ccd.29103
Volume 98, Issue 2 p. 407-408
Chronic total occlusion revascularization for ventricular arrhythmias?—Still more work to be done
Weeranun D. Bode MD,Michael F. Bode MD
doi : 10.1002/ccd.29133
Volume 98, Issue 2 p. 409-409
What have we learnt from the use of papyrus covered stent in France and Spain?
Alfonso Jurado-Roman MD, PhD,Ariana Gonzalvez MD,Santiago Jimenez-Valero MD,Guillermo Galeote MD, PhD,Raul Moreno MD, PhD,Esteban Lopez de Sa MD, PhD
doi : 10.1002/ccd.29469
Volume 98, Issue 2 p. 410-410
Reply to “what have we learnt from the use of Papyrus covered stent in France and Spain?”
Marco Hern?ndez-Enr?quez MD, PhD,Nicolas Boudou MD,Loic Belle MD
doi : 10.1002/ccd.29462
Volume 98, Issue 2 p. 411-412
Sex difference in long-term clinical outcomes after percutaneous coronary intervention: A propensity-matched analysis of National Health Insurance data in Republic of Korea
Seung-Hwa Lee MD,Jungmin Choi BPharm, MBA,Yoo-Jung Chang BA,Eun-Seok Shin MD, PhD,Ki-Hong Choi MD,Joo Myung Lee MD, PhD,Taek Kyu Park MD, PhD,Jeong Hoon Yang MD, PhD,Young Bin Song MD, PhD,Joo-Yong Hahn MD, PhD,Seung-Hyuk Choi MD, PhD,Hyeon-Cheol Gwon MD, PhD,Sang-Hoon Lee MD, PhD,Jin-Ho Choi MD, PhD
doi : 10.1002/ccd.29511
Volume 98, Issue 2 p. E171-E180
We investigated the gender difference in the 5-year outcome after percutaneous coronary intervention (PCI) using an unselected population data.
Randomized trial comparing radial hemostasis techniques; catechol conjugated chitosan pad (InnoSEAL) versus pneumatic compression band
Asad Z. Pathan MD, FACC, FSCAI,Saba Aijaz MBBS, FCPS, MSc,Sana Sheikh MBBS, MSc,Saadia Sattar MSc
doi : 10.1002/ccd.29578
Volume 98, Issue 2 p. E181-E187
Primary objectives: to compare radial artery occlusion rate (RAO) after cardiac catheterization between catecholamine-chitosan pad (InnoSEAL) and pneumatic compression device (PCD) and to compare difference in hemostasis time and radial monitoring termination time between two arms. Secondary objectives: to compare radial site bleeding and ease of use of two methods by cath-lab technicians.
Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial
Eline H. Ploumen MD,Rosaly A. Buiten MD, PhD,Paolo Zocca MD, PhD,Carine J. M. Doggen PhD,Gillian A. J. Jessurun MD, PhD,Carl E. Schotborgh MD,Ariel Roguin MD, PhD,Peter W. Danse MD, PhD,Edouard Benit MD,Adel Aminian MD,Rutger L. Anthonio MD, PhD,Samer Somi MD, PhD,Gerard C.M. Linssen MD, PhD,Marc Hartmann MD, PhD,Marlies M. Kok MD, PhD,Clemens von Birgelen MD, PhD
doi : 10.1002/ccd.29594
Volume 98, Issue 2 p. E188-E196
To compare 2-year outcome following treatment with drug-eluting stents (DES) for acute myocardial infarction (MI) versus non-MI clinical syndromes. In acute MI patients, a stent-level comparison was performed, comparing Resolute Onyx versus Orsiro stents.
Outcome of PCI with Xience versus other commonly used modern drug eluting stents: A SCAAR report
Per Grimfj?rd MD, PhD,Elin Bergman MD,Sergio Buccheri MD,David Erlinge MD, PhD,Bo Lagerqvist MD, PhD,Bodil Svennblad MSc, PhD,Sebastian V?lz MD, PhD,Oskar Anger?s MD, PhD,Stefan James MD, PhD
doi : 10.1002/ccd.29641
Volume 98, Issue 2 p. E197-E204
To analyze the clinical outcome of percutaneous coronary intervention (PCI) using the Xience drug eluting stent (DES) versus other modern DES.
Trends in the utilization and reimbursement of coronary revascularization in the United States Medicare population from 2010 to 2018
Aakash M. Shah BS,Emaad Siddiqui MD,Carlos Cuenca BS, MS,Persida Drotar MD,Alexis K. Okoh MD,Arash Salemi MD, FACS,Sergio Waxman MD, MBA,Justin Sambol MD
doi : 10.1002/ccd.29649
Volume 98, Issue 2 p. E205-E212
To determine utilization and reimbursement trends of coronary revascularization procedures in the US Medicare population from 2000 to 2018.
Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention
Tatsuhiko Otsuka MD,Yasushi Ueki MD,Raminta Kavaliauskaite MD,Thomas Zanchin MD,Sarah B?r MD,Stefan Stortecky MD,Thomas Pilgrim MD, MSc,Marco Valgimigli MD, PhD,Bernhard Meier MD,Dik Heg PhD,Stephan Windecker MD,Lorenz R?ber MD, PhD
doi : 10.1002/ccd.29650
Volume 98, Issue 2 p. E213-E221
We aimed to assess the ischemic and bleeding risks of single antiplatelet therapy (SAPT) with prasugrel compared with standard dual antiplatelet therapy (DAPT) (aspirin plus clopidogrel for 1 year) in patients with chronic coronary syndrome (CCS) treated with new generation drug-eluting stents (DES).
Timing of Impella implantation and outcomes in cardiogenic shock or high-risk percutaneous coronary revascularization
Giuseppe Tarantini MD,Giulia Masiero MD,Francesco Burzotta MD,Vittorio Pazzanese MD,Carlo Briguori MD,Carlo Trani MD,Tommaso Piva MD,Federico De Marco MD,Maurizio Di Biasi MD,Paolo Pagnotta MD,Marco Mojoli MD,Gavino Casu MD,Gennaro Giustino MD,Giulia Lorenzoni PhD,Matteo Montorfano MD,Marco B. Ancona MD,Federico Pappalardo MD,Alaide Chieffo MD,IMPella Mechanical Circulatory Support Device in Italy (IMP-IT) Registry authors
doi : 10.1002/ccd.29674
Volume 98, Issue 2 p. E222-E234
To evaluate the role of the microaxial percutaneous mechanical circulatory support device (Impella® pump) implantation pre-percutaneous coronary intervention (PCI) versus during/after PCI in cardiogenic shock (CS) and high-risk PCI populations.
Impact of extended dual antiplatelet therapy on long-term prognosis in patients with acute coronary syndrome complicated with anemia: A sub-analysis of the real-world OPT-CAD study
Yu Zhao MD,Jing Li MD,Sicong Ma MD,Zaixin Jiang MD,Zhiguo Li MD,Xiaozeng Wang MD,Yaling Han MD, FAHA, FACC,Yi Li MD, FACC
doi : 10.1002/ccd.29676
Volume 98, Issue 2 p. E235-E242
To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12?months on long-term prognosis in acute coronary syndrome (ACS) patients complicated with anemia undergoing percutaneous coronary intervention (PCI).
Multicenter clinical evaluation of a piezoresistive-MEMS-sensor rapid-exchange pressure microcatheter system for fractional flow reserve measurement
Chenguang Li MD,Junqing Yang MD,Shaohong Dong MD,Liang Dong MD,Jiyan Chen MD,Li Shen MD,Feng Zhang MD,Changling Li MD,Huadong Liu MD,Xinyang Hu MD,William Kongto Hau PhD,Juying Qian MD,Allen Jeremias MD, MSc,Jian'an Wang MD,Junbo Ge MD,for the SUPREME Study Investigators
doi : 10.1002/ccd.29678
Volume 98, Issue 2 p. E243-E253
This multicenter, prospective clinical study investigates whether the microelectromechanical-systems-(MEMS)-sensor pressure microcatheter (MEMS-PMC) is comparable to a conventional pressure wire in fractional flow reserve (FFR) measurement.
Outcomes of rotational atherectomy for severely calcified coronary lesions: A single center 5-year experience
Wei Gao MD, PhD,Yaolin Chen MD,Hongbo Yang MD, PhD,Kang Yao MD, PhD,Junbo Ge MD, PhD
doi : 10.1002/ccd.29740
Volume 98, Issue 2 p. E254-E261
The aim of this study was to investigate the influences of accumulated experience on rotational atherectomy (RA) operation regarding to in-hospital outcomes in the drug-eluting stent (DES) era.
Comparison of the investigational device exemption and post-approval trials of the Melody transcatheter pulmonary valve
Jacqueline Kreutzer MD,Aimee K. Armstrong MD,Jonathan J. Rome MD,Thomas M. Zellers MD,David T. Balzer MD,Jeffrey D. Zampi MD,Allison K. Cabalka MD,Alexander J. Javois MD,Daniel R. Turner MD,Robert G. Gray MD,John W. Moore MD,Shicheng Weng MS,Thomas K. Jones MD,Danyal M. Khan MD,Julie A. Vincent MD,William E. Hellenbrand MD,John P. Cheatham MD,Lisa J. Bergersen MD, MPH,Doff B. McElhinney MD
doi : 10.1002/ccd.29657
Volume 98, Issue 2 p. E262-E274
We compared 5-year outcomes of transcatheter pulmonary valve (TPV) replacement with the Melody TPV in the post-approval study (PAS) and the investigational device exemption (IDE) trial.
Right ventricular outflow tract stenting in symptomatic infants without the use of a long delivery sheath
Niall Linnane MD,Mohamed Al Nasef MD,Colin J. McMahon MD,Jonathan McGuinness MD, PhD,Brian McCrossan MD,Paul Oslizlok MD,Kevin P. Walsh MD,Damien Kenny MD
doi : 10.1002/ccd.29708
Volume 98, Issue 2 p. E275-E281
Right ventricular outflow tract (RVOT) stenting improves systemic oxygenation and facilitates pulmonary arterial growth in symptomatic infants prior to repair of tetralogy of Fallot. The aim of this study was to evaluate the safety and efficacy of RVOT stenting without the use of a long delivery sheath.
Impact of early hospital discharge on clinical outcomes after transcatheter aortic valve implantation
Pernille S. B?kke MD,Troels H. J?rgensen MD, PhD,Lars S?ndergaard MD, DMSc
doi : 10.1002/ccd.29403
Volume 98, Issue 2 p. E282-E290
Early discharge after transcatheter aortic valve implantation (TAVI) may potentially impact post-procedural safety of the patient. The study aim was to compare safety of TAVI in patients planned for fast track hospital stay with patients planned for standard hospital stay.
Transaxillary transcatheter ACURATE neo aortic valve implantation – The TRANSAX multicenter study
Ignacio J. Amat-Santos MD PhD,Sandra Santos-Mart?nez MD,Lenard Conradi MD,Maurizio Taramasso MD PhD,Arnaldo Poli MD,Rafael Romaguera MD,Manuel Pan MD PhD,Rodrigo Bagur MD,Raquel del Valle MD,Luis Nombela-Franco MD PhD,Oliver D. Bhadra MD,?lvaro Aparisi MD,Alfredo Redondo MD,Hip?lito Gutiérrez MD,Itziar G?mez MsC,J. Alberto San Roman MD PhD
doi : 10.1002/ccd.29423
Volume 98, Issue 2 p. E291-E298
Transcatheter aortic valve replacement (TAVR) via transaxillary (TAx) approach with ACURATE neo valve is an off-label procedure. Our aim was to gather information on ACURATE neo cases implanted via TAx approach and report major outcomes.
Self-expanding transcatheter aortic valve infolding: Current evidence, diagnosis, and management
Marco Bruno Ancona MD,Alessandro Beneduce MD,Vittorio Romano RT,Nicola Buzzatti MD,Filippo Russo MD,Barbara Bellini MD,Luca Angelo Ferri MD,Eustachio Agricola MD,Giovanni Landoni MD,Anna Mara Scandroglio MD,Alaide Chieffo MD,Matteo Montorfano MD
doi : 10.1002/ccd.29432
Volume 98, Issue 2 p. E299-E305
Prosthetic valve infolding is a rare but severe complication of transcatheter aortic valve implantation (TAVI) with self-expanding valves. However, currently available clinical data are limited and fragmented.
Papillary muscle rupture after transcatheter aortic valve implantation
Yusuke Morita MD,Akihiro Endo MD, PhD,Kazuaki Tanabe MD, PhD
doi : 10.1002/ccd.29252
Volume 98, Issue 2 p. E306-E309
Catheter-induced mitral regurgitation (MR) caused by mitral papillary muscle rupture can be a fatal complication of transcatheter aortic valve implantation (TAVI). We report a case involving an 89-year-old man who presented with symptomatic severe aortic stenosis. In addition, preoperative echocardiography showed accessory mitral valve tissue. Although moderate MR developed immediately after TAVI, severe MR caused by anterolateral papillary muscle rupture occurred 3?months after TAVI. As only a few case series have been published, our case report adds to the evidence base for this treatment strategy.
A safe and simple method for axIABP placement using a left axillary–radial technique
Benjamin Maatman MD,Hugo Rios-Meza MD,Maya Guglin MD,George Revtyak MD, FACC, FSCAI
doi : 10.1002/ccd.29283
Volume 98, Issue 2 p. E310-E314
In patients with severe heart failure, a percutaneous axillary intraaortic balloon pump (axIABP) may permit ambulation while awaiting destination therapy. Traditionally, an “axillary–femoral” approach has been used with femoral access for axillary angiography during insertion. We describe an “axillary–radial” technique for axIABP insertion and removal using the left radial artery.
Potential risk of perioperative thromboembolism in patients with antiphospholipid syndrome who undergo transcatheter aortic valve implantation: A case series
Tomoya Hoshi MD,Daigo Hiraya MD,Akira Sato MD,Masaki Ieda MD
doi : 10.1002/ccd.29300
Volume 98, Issue 2 p. E315-E319
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by a positive serum antiphospholipid antibody status. Patients with APS usually have an underlying hypercoagulable state, which can increase the risk of perioperative thromboembolism. We describe three patients with APS who underwent transcatheter aortic valve implantation for symptomatic severe aortic stenosis. Of them, two had complicated cerebrovascular events, and the other had no complications. Careful antithrombotic management is essential to minimize the risk of thromboembolism and bleeding in patients with APS.
Equipment entrapment during redo-TAVR with successful BASILICA procedure
Waqas T. Qureshi MD, MS,Matthew Parker MD,Jennifer Walker MD,Nikolaos Kakouros MBBS, MD(Res), PhD
doi : 10.1002/ccd.29485
Volume 98, Issue 2 p. E320-E323
Transcatheter aortic valve replacement (TAVR) for transcatheter heart valve failure has been suggested for high-risk patients. TAVR-in-TAVR, however, may lead to complex leaflet interactions causing coronary ostial obstruction, which is a devastating complication. Coronary protection with provisional stent placement may be challenging. We describe the first percutaneous transaxillary case of TAVR-in-TAVR with Bioprosthetic Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA) where guide catheters used for coronary protection were entrapped between the valve frames. We describe anatomical predictors and management considerations. Operators should be aware of this important complication during TAVR-in-TAVR valve placement.
Implication of Impella-supported percutaneous coronary intervention
Teruhiko Imamura MD, PhD
doi : 10.1002/ccd.29122
Volume 98, Issue 2 p. E324-E324
Letter to the Editor concerning the article: “Comparison of drug eluting versus bare metal stents”
I?aki Navarro Castellanos MD,Nagib Dahdah MD, FACC, FRCPC
doi : 10.1002/ccd.29135
Volume 98, Issue 2 p. E325-E325
Trends in cardiovascular procedural volumes in the setting of COVID-19: Insights from the VA clinical assessment, reporting, and tracking program
Stephen W. Waldo MD,Mary E. Plomondon PhD,Colin I. O'Donnell PhD,Paul A. Heidenreich MD,Merritt H. Riatt,Jennifer Ballard-Hernandez DNP,José Ortiz MD,Paul D. Varosy MD,Mladen I. Vidovich MD,Christopher J. O'Donnell MD MPH,Richard Schofield MD
doi : 10.1002/ccd.29204
Volume 98, Issue 2 p. E326-E328
Thrombocytopenia after TAVI in patients with low body mass index
Flavio Rimmaudo MD,Gianmarco Angelini MD,Ignazio Condello PhD
doi : 10.1002/ccd.29675
Volume 98, Issue 2 p. E329-E331
